RAIN News and Press, Rain Therapeutics Inc. From 05/30/23

2023-05-30 11:02:01 ET Rain Oncology ( NASDAQ: RAIN ) shed ~9% in the morning hours Tuesday after announcing layoffs, the departure of the company’s chief medical officer, and changes to its clinical programs for lead candidate milademetan. As part of efforts to strea...

– Company plans to suspend enrollment in the ongoing milademetan Phase 2 MANTRA-2 basket trial and terminate plans for its Phase 1/2 MANTRA-4 combination trial – – Evaluation of outcomes from the MANTRA Phase 3 milademetan trial in dedifferentiated liposarcoma (DD L...

2023-05-23 09:17:14 ET Rain Oncology ( NASDAQ: RAIN ) continued to fall in the pre-market Tuesday after multiple analysts downgraded the company on its decision to halt studies for its lead asset, milademetan in liposarcoma, following a Phase 3 setback. RAIN fell ~88% on Monday ...

2023-05-22 15:15:00 ET Shares of Rain Oncology (NASDAQ: RAIN) were down 87% Monday afternoon after the precision oncology company released top-line results for its lead therapy, milademetan, to treat dedifferentiated liposarcoma, a type of cancer affecting fatty tissue, usually in t...

2023-05-22 10:03:29 ET Gainers: Microbot Medical ( MBOT ) +46% . Hepion Pharmaceuticals ( HEPA ) +41% . Atea Pharmaceuticals ( AVIR ) +38% . VectivBio Holding ( VECT ) +37% . CNS Pharmaceuticals ( CNSP ) +23% . Losers: Rain Oncology ( ...

– The Phase 3 MANTRA trial did not meet the primary endpoint of progression free survival vs. standard of care – – The median PFS was 3.6 months for milademetan versus 2.2 months for trabectedin with a hazard ratio of 0.89 – – Rain to host a co...

2023-05-19 15:00:19 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...

2023-05-13 03:42:09 ET Rain Oncology, Inc. (RAIN) Q1 2023 Earnings Conference Call May 11, 2023, 5:00 pm ET Company Participants Dan Ferry - IR, LifeSci Advisors Avanish Vellanki - CEO Robert Doebele - CSO Richard Bryce - CMO Nelson Cabatuan - SVP, Financ...

2023-05-11 16:35:44 ET Rain Oncology press release ( NASDAQ: RAIN ): Q1 GAAP EPS of -$0.56 beats by $0.05 . As of March 31, 2023, Rain had $109.8 million in cash, cash equivalents and short-term investments. Consistent with the prior quarter, Rain ( RAIN ) will...

– Quarter-end cash position of $110 million provides runway to complete all ongoing and planned clinical trials of milademetan, including the Phase 3 MANTRA trial in liposarcoma, Phase 2 MANTRA-2 basket trial, and planned Phase 1/2 MANTRA-4 basket trial – – Required...